Finally, because of the propensity for neurofibromatosis type 2 patients to develop schwannomas, genetic testing for the neurofibromatosis mutation as well as merlin, a tumor suppressor gene localized on chromosome 22q12, should be performed in patients diagnosed with spinal cord schwannomas. The gene discussed is NF2; the disease is neurofibromatosis.